Bioequivalence Study of Sorafenib Tablet and Nexavar

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Fasting
Interventions
DRUG

Nexavar

"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."

DRUG

Sorafenib

"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.~Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."

Trial Locations (1)

G1P 0A2

Inventiv Health Clinique Inc., Québec

All Listed Sponsors
lead

Yabao Pharmaceutical Group

INDUSTRY

NCT02599337 - Bioequivalence Study of Sorafenib Tablet and Nexavar | Biotech Hunter | Biotech Hunter